Drug intelligence / Profile preview

ATL1101

Development stage: Preclinical
Lead developer: Antisense Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Topical, Intraperitoneal

Overview

ATL1101 is a second-generation antisense pharmaceutical developed by Antisense Therapeutics. It was in-licensed as part of a development pipeline from Isis Pharmaceuticals (now Ionis Pharmaceuticals). ATL1101 is being investigated for its potential use in treating cancer. As an antisense oligonucleotide, its mechanism of action typically involves sequence-specific binding to target mRNA, which can lead to the degradation of the mRNA or inhibition of its translation, thereby reducing the production of disease-associated proteins.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on ATL1101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATL1101.

Explore the full profile